The market has rewarded this biotech for its breakthroughs.
JNJ Johnson & Johnson
XNYS
263.81
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
JNJ
$263.81
—
Key stats
$263.81
- 52-Week Range
- $184.66 – $281.07
- YTD
- +27.23%
- IV Rank (30D)
- 50.59
- Straddle Price
- $14.62
- P/C Vol Ratio
- 0.68
- Market Cap
- $644.2B
- Open
- $265.82
- Day Range
- $262.40 – $266.02
- Volume
- 5,309,548
- Prev Close
- $267.61
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.12% |
| Beta vs SPY | 0.46 |
| Cost of Equity (CAPM) | 7.44% (VRP-adj) |
| WACC | 7.38% |
| Volatility Risk Premium | +18.0pp (IV − HV30) |
| Effective Tax Rate | 9.3% |
| Rev. Growth (YoY, DCF input) | +3.4% |
| DCF Horizon | 12 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $20.2B |
| Return on Equity (TTM) | 19.7% |
| Book / Price | 12.5% |
| Gross Margin (TTM) | 67.6% |
| FCF Margin (TTM) | 20.3% |
| Debt / Equity | 0.44 |
| Quality Score | 5/6 — high quality (12y DCF) |
| Market-Implied Growth | +9.3% (reverse-DCF on current price) |
| SMA 50 | $265.17 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $259.39 |
| Bollinger Width / SMA20 | 3.8% (drives anchor stability) |
| Net Debt | $18.9B |
| Market Cap | $654B |
Peers used for multiples: ABBV, AMGN, BMY, GILD, LLY, MRK, PFE, UNH
60-Day Conviction
76%
20-Day Fair Value
≈ by Nov 23, 2026
$265.27
α +0.6%
rank 3%
conviction
36%
40-Day Fair Value
≈ by Dec 22, 2026
$271.34
α +2.9%
rank 8%
conviction
83%
60-Day Fair Value
≈ by Jan 20, 2027
$270.47
α +2.5%
rank 10%
conviction
76%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $177.00 | 16% | |
| DDM (Gordon) | $169.54 | 13% | |
| Peer P/E | $267.59 | 7% | median 39.3× · 7 peers |
| Peer EV/EBITDA | $249.32 | 7% | median 18.3× · 8 peers |
| Peer P/B | $294.10 | 1% | median 8.8× · 7 peers |
| Peer P/S | $247.22 | 5% | median 5.9× · 8 peers |
| Market Anchor (SMA50) | $265.17 | 33% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | $270.01 | 16% | 41 strikes · skew -0.12 |
As of 2026-10-23 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNYS
- Market Cap
- $644.2B
- Employees
- 140,800
- List Date
- 1944-09-25
- CIK
- 0000200406
- Headquarters
- New Brunswick, NJ
- Homepage
- https://www.jnj.com
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 4.24% | 0.44% | -8.29% | -0.67% | 5.65% | 9.60% | 1.83% |
| Feb | -2.61% | -3.69% | -7.07% | 1.91% | 8.66% | 7.66% | 0.81% |
| Mar | 3.16% | 8.07% | 1.59% | -2.42% | -0.86% | -1.66% | 1.31% |
| Apr | -0.06% | 1.27% | 4.37% | -8.36% | 2.00% | -5.85% | -1.10% |
| May | 2.45% | 0.50% | -5.22% | -2.98% | 0.49% | -0.82% | -0.93% |
| Jun | -0.48% | -0.11% | 7.10% | -1.07% | -1.71% | 13.63% | 2.89% |
| Jul | 3.76% | -2.79% | 2.56% | 7.79% | 5.66% | 1.30% | 3.05% |
| Aug | 0.50% | -7.23% | -4.27% | 3.17% | 5.88% | 4.50% | 0.42% |
| Sep | -7.05% | -1.20% | -2.95% | -3.05% | 4.13% | -2.38% | -2.08% |
| Oct | 1.50% | 6.60% | -4.39% | -1.31% | 1.52% | 1.99%* | 0.98% |
| Nov | -4.35% | 2.84% | 4.02% | -3.20% | 11.09% | -- | 2.08% |
| Dec | 8.22% | -1.17% | -1.04% | -6.58% | 0.78% | -- | 0.04% |
| Total | 8.67% | 2.60% | -13.98% | -16.40% | 51.82% | 29.76% | 10.41% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $259.02
SMA 50: $265.20
SMA 200: $245.47
Current: $263.81
EMA 12: $259.66
EMA 26: $260.82
MACD: -1.1606 | Signal: 1.1368
BEARISH
ADX (14): 14.72
RANGE
+DI: 34.51
−DI: 24.94
Momentum Oscillators
RSI (14): 53.02
NEUTRAL
Stoch %K: 77.76
Stoch %D: 71.19
Williams %R: -23.92
Volume & Volatility
BB Upper: $270.66
BB Lower: $247.39
NEUTRAL
OBV: 330,749,773
Vol SMA 20: 7,938,644
Vol ROC: -7.31%
ATR: $6.35
True Range: $5.21
HV 20: 32.7%
HV 30: 26.8%
HV 60: 23.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-25T00:00:00 – 2026-10-23T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall assessment: BEARISH with confidence level (6/10)
Key drivers:
- Overbought RSI and Stochastic indicators
- Weak trend signal from ADX and DMI
- Negative beta indicating stock moves opposite to market
Primary risks:
- Potential sell-off due to overbought conditions
- Market weakness could exacerbate bearish sentiment
Investment thesis: Johnson & Johnson (JNJ) is experiencing a short-term correction, driven by market factors and technical indicators. The stock's negative beta and weak trend signal suggest it may continue to move opposite the broader market.
Recent news sentiment impact:
- Neutral headlines dominate recent news, with no significant impact on sentiment
Technical Analysis
Trend Direction: Short-term (1-4 weeks): BEARISH; Medium-term (1-3 months): NEUTRAL; Long-term (3-12 months): BULLISH
Support/Resistance Levels:
- Key price levels: $250.92 (lower Bollinger Band), $261.51 (SMA 20)
- Resistance: $272.10 (upper Bollinger Band)
Momentum Signals:
- RSI interpretation: Overbought (>70) with a value of 70.07
- MACD signal: Bullish momentum (4.05 / Signal: 1.01 / Histogram: 3.04)
- Bollinger Bands position: Overbought
Volume Analysis:
- Volume trends: Weak volume flow suggests reduced market interest
- Institutional interest signals: Low put-call ratio and OI, indicating bearish sentiment
News & Sentiment Analysis
Recent Headlines Summary: Neutral headlines dominate recent news, with no significant impact on sentiment
Sentiment Assessment: Aggregate news sentiment is NEUTRAL
Catalyst Identification: No significant catalysts in the near term
Market Narrative: Recent market weakness has not had a significant impact on JNJ's stock price
Risk & Volatility Assessment
Beta Interpretation: Negative beta (-0.22) indicating stock moves opposite to market
Volatility Regime: High volatility (Historical Volatility: 26.0%)
Options Market Signals:
- IV rank: Medium (42.2%)
- Put-call ratio: 0.38 (Bullish sentiment)
- Open interest: 63,848 calls vs 34,201 puts
Downside Protection: Support levels and risk management considerations are key
Market Context & Positioning
Sector Performance: Healthcare sector is performing well, with JNJ's stock price reflecting this trend
Institutional Activity: Low institutional interest suggests reduced market participation
Correlation Analysis: JNJ's stock moves opposite to the broader market (negative beta)
Relative Valuation: JNJ's stock price is relatively strong within its trading range
Key Levels & Action Items
Critical Price Levels:
- Support: $250.92 (lower Bollinger Band)
- Resistance: $272.10 (upper Bollinger Band)
Breakout/Breakdown Levels:
- Breakout above $272.10 could signal a return to bullish momentum
- Breakdown below $250.92 could indicate further weakness
Time-Sensitive Catalysts: No significant catalysts in the near term
Risk Management:
- Stop-loss levels: Consider placing stop-loss orders at $260.00 or lower
- Position sizing considerations: Reduce position size to manage risk
Generated
News
All JNJ news →
Looking beyond near-term headwinds paints a fairly bright picture of Johnson & Johnson’s outlook.
The guidance bump doesn't matter nearly as much as investors' response to the company's Q3 report suggests.
Bristol-Myers trades at a significant valuation discount, but its higher leverage and patent risks contrast sharply with Johnson & Johnson's diversified stability.
MedTech growth stalled while pharma surged, leaving the company to bet on new product launches and a planned spin-off to restore momentum.
Innovative Medicine drove 7.9% growth as revenue hit $25.4 billion.
Showing 1–10 of 47
Page 1 of 5
Earnings History
18 of 24 under expected move
Avg Expected Move
2.69%
Avg Actual Move
2.00%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-01-26 | Pre-Market | 4.22% | 2.71% | 0.64x | Within |
| 2021-04-20 | Pre-Market | 2.01% | 2.33% | 1.16x | Exceeded |
| 2021-07-21 | Pre-Market | 2.24% | 0.62% | 0.28x | Within |
| 2021-10-19 | Pre-Market | 2.58% | 2.34% | 0.91x | Within |
| 2022-01-25 | Pre-Market | 3.19% | 2.86% | 0.90x | Within |
| 2022-04-19 | Pre-Market | 2.31% | 3.05% | 1.32x | Exceeded |
| 2022-07-19 | Pre-Market | 2.89% | 1.46% | 0.51x | Within |
| 2022-10-18 | Pre-Market | 2.58% | 0.35% | 0.14x | Within |
| 2023-01-24 | Pre-Market | 2.54% | 0.00% | 0.00x | Within |
| 2023-04-18 | Pre-Market | 2.27% | 2.81% | 1.24x | Exceeded |
| 2023-07-20 | Pre-Market | 2.45% | 6.07% | 2.48x | Exceeded |
| 2023-10-17 | Pre-Market | 2.59% | 0.91% | 0.35x | Within |
| 2024-01-23 | Pre-Market | 2.42% | 1.64% | 0.68x | Within |
| 2024-04-16 | Pre-Market | 2.82% | 2.13% | 0.76x | Within |
| 2024-07-17 | After-Close | 1.43% | 0.74% | 0.52x | Within |
| 2024-10-15 | Pre-Market | 2.65% | 1.55% | 0.58x | Within |
| 2025-01-22 | Pre-Market | 2.43% | 1.94% | 0.80x | Within |
| 2025-04-15 | Pre-Market | 2.70% | 0.48% | 0.18x | Within |
| 2025-07-16 | Pre-Market | 2.57% | 6.19% | 2.41x | Exceeded |
| 2025-10-14 | Pre-Market | 3.23% | 0.03% | 0.01x | Within |
| 2026-01-21 | Pre-Market | 3.26% | 0.09% | 0.03x | Within |
| 2026-04-14 | Pre-Market | 3.51% | 0.90% | 0.26x | Within |
| 2026-07-15 | After-Close | 2.14% | 1.19% | 0.56x | Within |
| 2026-10-13 | Pre-Market | 3.58% | 5.73% | 1.60x | Exceeded |
Earnings calendar: this week’s reports with expected vs actual moves →
JNJ Options Activity & IV Rank
JNJ IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 25.2%
7-DTE IV: 23.9%
Expected Move: $14.62
7-DTE Move: $7.21
Days to Exp: 28 (2026-11-20)
Options Flow
Call Volume: 1,344
Put Volume: 914
P/C Volume: 0.68
BULLISH
Call OI: 17,155
Put OI: 11,857
P/C OI: 0.691
Total OI: 29,012
ATM Options Pricing
ATM Call: $7.15
ATM Put: $7.47
Call %: 2.7%
Put %: 2.8%
Chain Summary
Chain Volume: 48,351
Chain OI: 363,306
Last Updated: 10/23/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 20th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
20%
vs own history
GEX tilt
+0.06
OI-weighted, today
Vanna tilt
+0.58
δ-sensitivity to IV
Charm tilt
-0.65
δ-decay vs time
Vanna tilt +0.58: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.65: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 181 ATM contracts, 139k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
25%
+2.1
pts
EXTREME
as of Oct 23 · ATM 24.4% / Wing 26.6%
30 DTE / 10d
3%
+0.2
pts
EXTREME
as of Oct 23 · ATM 24.9% / Wing 25.1%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)23.7LowOct 23
IV Rank (30 DTE)50.6MediumOct 23
Straddle Price (30 DTE)$14.62Oct 23
Beta Analysis
Risk Metrics
Beta: -0.2283
Alpha: 36.85%
Correlation: -0.1396
R-Squared: 1.9%
Stock Volatility: 20.8%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Negative beta - stock moves opposite to market
Negative beta - stock moves opposite to market
Beta & Alpha Over Time
JNJ Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 2,445,000,000 (as of 2026-09-27)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
67 filers$5.29B notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $969.20M | 18.33% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $933.01M | 17.65% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $702.96M | 13.29% | 2026-06-30 |
| 4 | JPMorgan Chase & Co Custodian | $328.70M | 6.22% | 2026-06-30 |
| 5 | Royal Bank of Canada Custodian | $324.45M | 6.14% | 2026-06-30 |
| 6 | D. E. Shaw & Co., Inc. Custodian | $217.32M | 4.11% | 2026-06-30 |
| 7 | PEAK6 LLC | $186.67M | 3.53% | 2026-06-30 |
| 8 | IMC-Chicago, LLC Custodian | $180.70M | 3.42% | 2026-06-30 |
| 9 | Wolverine Trading, LLC Custodian | $136.00M | 2.57% | 2025-09-30 |
| 10 | Millennium Management LLC Custodian | $111.57M | 2.11% | 2026-06-30 |
| 11 | Walleye Trading LLC | $94.55M | 1.79% | 2026-06-30 |
| 12 | Citigroup Inc. Custodian | $91.63M | 1.73% | 2026-06-30 |
| 13 | National Bank of Canada Custodian | $88.89M | 1.68% | 2026-06-30 |
| 14 | GROUP ONE TRADING LLC Custodian | $73.45M | 1.39% | 2026-06-30 |
| 15 | UBS Group AG Custodian | $70.32M | 1.33% | 2026-06-30 |
| 16 | Point72 Asset Management, L.P. | $65.09M | 1.23% | 2026-06-30 |
| 17 | Squarepoint Ops LLC | $62.17M | 1.18% | 2026-06-30 |
| 18 | Walleye Capital LLC | $48.18M | 0.91% | 2026-06-30 |
| 19 | Simplex Trading, LLC Custodian | $47.42M | 0.90% | 2026-06-30 |
| 20 | Alphadyne Asset Management LP | $43.07M | 0.81% | 2026-06-30 |
| 21 | Gladius Capital Management LP | $39.97M | 0.76% | 2026-06-30 |
| 22 | Man Group plc | $38.10M | 0.72% | 2026-06-30 |
| 23 | Goldman Sachs Group Inc Custodian | $36.14M | 0.68% | 2026-06-30 |
| 24 | BNP Paribas Financial Markets Custodian | $36.14M | 0.68% | 2026-06-30 |
| 25 | TUDOR INVESTMENT CORP ET AL | $34.39M | 0.65% | 2026-06-30 |
65 filers$5.60B notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $1.01B | 17.97% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $974.91M | 17.41% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $816.26M | 14.57% | 2026-06-30 |
| 4 | Point72 Asset Management, L.P. | $483.84M | 8.64% | 2026-06-30 |
| 5 | Citigroup Inc. Custodian | $461.44M | 8.24% | 2026-06-30 |
| 6 | Millennium Management LLC Custodian | $287.19M | 5.13% | 2026-06-30 |
| 7 | IMC-Chicago, LLC Custodian | $184.84M | 3.30% | 2026-06-30 |
| 8 | NOMURA HOLDINGS INC | $136.51M | 2.44% | 2026-06-30 |
| 9 | UBS Group AG Custodian | $115.67M | 2.07% | 2026-06-30 |
| 10 | BNP Paribas Financial Markets Custodian | $94.10M | 1.68% | 2026-06-30 |
| 11 | JPMorgan Chase & Co Custodian | $90.84M | 1.62% | 2026-06-30 |
| 12 | CAPSTONE INVESTMENT ADVISORS, LLC | $90.08M | 1.61% | 2026-06-30 |
| 13 | GROUP ONE TRADING LLC Custodian | $87.37M | 1.56% | 2026-06-30 |
| 14 | Alphadyne Asset Management LP | $61.79M | 1.10% | 2026-06-30 |
| 15 | Qube Research & Technologies Ltd | $59.43M | 1.06% | 2026-06-30 |
| 16 | Wolverine Trading, LLC Custodian | $56.12M | 1.00% | 2025-09-30 |
| 17 | Eisler Capital Management Ltd. | $50.43M | 0.90% | 2025-09-30 |
| 18 | Simplex Trading, LLC Custodian | $45.05M | 0.80% | 2026-06-30 |
| 19 | D. E. Shaw & Co., Inc. Custodian | $39.49M | 0.71% | 2026-06-30 |
| 20 | Man Group plc | $38.10M | 0.68% | 2026-06-30 |
| 21 | Allianz Asset Management GmbH | $34.46M | 0.62% | 2026-06-30 |
| 22 | Parallax Volatility Advisers, L.P. | $33.02M | 0.59% | 2026-06-30 |
| 23 | Squarepoint Ops LLC | $32.76M | 0.58% | 2026-06-30 |
| 24 | CAPITAL FUND MANAGEMENT S.A. | $30.70M | 0.55% | 2026-06-30 |
| 25 | Walleye Trading LLC | $30.50M | 0.54% | 2026-06-30 |
JNJ Insider Trading (Form 4)
Latest: 2026-09-10Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-10 | Eugene A. Woods | Director | Grant (A) | +135 RSU | — | EDGAR | |
| 2026-09-10 | Daniel E Pinto | Director | Grant (A) | +113 RSU | — | EDGAR | |
| 2026-09-10 | Marillyn A Hewson | Director | Grant (A) | +180 RSU | — | EDGAR | |
| 2026-09-04 | Timothy Schmid | EVP, WW Chair, MedTech | Mixed | — | $209.87 | -$4.36M | EDGAR |
| 2026-08-18 | Jennifer L Taubert | EVP, WWC. Innovative Medicine | Mixed | — | $189.51 | -$2.22M | EDGAR |
| 2026-08-14 | Joaquin Duato | CEO and Chairman of the Board | Mixed | — | $188.42 | -$17.94M | EDGAR |
| 2026-08-07 | Joaquin Duato | CEO and Chairman of the Board | Sell (S) | −48,480 | $258.15 | -$12.52M | EDGAR |
| 2026-08-07 | Elizabeth Forminard | EVP, Chief Legal Officer | Mixed | −6,574 | $210.74 | -$2.86M | EDGAR |
| 2026-08-07 | Joaquin Duato | CEO and Chairman of the Board | Sell (S) | −48,480 | $258.15 | -$12.52M | EDGAR |
| 2026-08-07 | Elizabeth Forminard | EVP, Chief Legal Officer | Mixed | −6,574 | $210.74 | -$2.86M | EDGAR |
| 2026-07-21 | Vanessa Broadhurst | EVP, Global Corp Affairs | Mixed | — | $191.02 | -$2.78M | EDGAR |
| 2023-07-27 | William Hait | See Remarks | Mixed | — | $131.22 | -$1.20M | EDGAR |
| 2023-07-27 | Peter Fasolo | Exec VP, Chief HR Officer | Sell (S) | −20,000 | $170.32 | -$3.41M | EDGAR |
| 2023-06-14 | Kathryn E Wengel | EVP, Chief TO and Risk Officer | Sell (S) | −12,465 | $160.00 | -$1.99M | EDGAR |
| 2023-06-08 | Marillyn A Hewson | Director | Grant (A) | +230 RSU | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
JNJ Insider Holdings
6 insiders · @ $263.81
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Joaquin Duato | CEO and Chairman of the Board | 379,300 | $100.06M | -$69.19M | 20 | 2026-08-14 |
| 2 | Jennifer L Taubert | EVP, WWC. Innovative Medicine | 209,451 | $55.26M | -$17.55M | 12 | 2026-08-18 |
| 3 | Vanessa Broadhurst | EVP, Global Corp Affairs | 34,132 | $9.00M | -$5.79M | 5 | 2026-07-21 |
| 4 | Elizabeth Forminard | EVP, Chief Legal Officer | 32,912 | $8.68M | -$8.18M | 4 | 2026-08-07 |
| 5 | Timothy Schmid | EVP, WW Chair, MedTech | 25,493 | $6.73M | -$9.23M | 1 | 2026-09-04 |
| 6 | Marillyn A Hewson | Director | 3,000 | $791.4K | $419.0K | 20 | 2026-09-10 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
JNJ Board & Officers
As of SEC filings through Sep 10, 2026Directors 13
- Mark B. McClellan · since Oct 15, 2013
- Mary C Beckerle · since Jun 9, 2015
- Jennifer A Doudna · since Apr 26, 2018
- Marillyn A Hewson · since Apr 25, 2019
- Hubert Joly · since Dec 5, 2019
- Mark A Weinberger · since Dec 5, 2019
- Nadja West · since Dec 3, 2020
- Joaquin Duato · listed since Jan 2022
- Darius Adamczyk · since Feb 15, 2022
- Paula A Johnson · since Feb 14, 2023
- Eugene A. Woods · since Nov 30, 2023
- Daniel E Pinto · since Jul 1, 2025
- John G Morikis · since Sep 8, 2025
Officers 12
- Joaquin Duato · CEO and Chairman of the Board · listed since Jan 2023
- Joseph J Wolk · Exec VP, CFO · since Jul 2, 2018
- Kathryn E Wengel · EVP, Chief TO and Risk Officer · listed since Feb 2023
- Kristen Mulholland · EVP, Chief HR Officer · since Oct 1, 2024
- Elizabeth Forminard · EVP, Chief Legal Officer · listed since Feb 2026
- Vanessa Broadhurst · EVP, Global Corp Affairs · listed since Feb 2023
- Timothy Schmid · EVP, WW Chair, MedTech · since Oct 23, 2023
- James D. Swanson · EVP, CIO · listed since Feb 2024
- Jennifer L Taubert · EVP, WWC. Innovative Medicine · listed since Feb 2024
- John C Reed · EVP, Innovative Medicine, R&D · listed since Feb 2024
- Thomas Cavanaugh · EVP WW Chair, Innovative Med. · since Sep 1, 2026
- Robert J Decker · VP Corporate Controller · listed since Feb 2023
Changes in the last 10 years (52)
| Sep 1, 2026 | Thomas Cavanaugh became EVP WW Chair, Innovative Med. |
| Feb 6, 2026 | Elizabeth Forminard listed as EVP, Chief Legal Officer (previously Executive VP, General Counsel) in SEC filings |
| Sep 8, 2025 | John G Morikis became a director |
| Jul 1, 2025 | Daniel E Pinto became a director |
| Oct 15, 2024 | D Scott Davis reported in an SEC filing no longer being a director |
| Oct 1, 2024 | Kristen Mulholland became EVP, Chief HR Officer |
| Feb 20, 2024 | John C Reed listed as EVP, Innovative Medicine, R&D (previously EVP, Pharmaceuticals R&D) in SEC filings |
| Feb 14, 2024 | Jennifer L Taubert listed as EVP, WWC. Innovative Medicine (previously EVP, WW Chair, Pharmaceuticals) in SEC filings |
| Feb 14, 2024 | James D. Swanson listed as EVP, CIO (previously EVP, Chief Information Officer) in SEC filings |
| Nov 30, 2023 | Eugene A. Woods became a director |
| Oct 23, 2023 | Timothy Schmid became EVP, WW Chair, MedTech |
| Oct 23, 2023 | The company announced the departure of Ashley McEvoy as EVP, WW Chair, MedTech in an SEC filing |
| Apr 3, 2023 | John C Reed became EVP, Pharmaceuticals R&D |
| Mar 31, 2023 | The company announced the departure of Ian Davis from the board in an SEC filing |
| Feb 14, 2023 | Vanessa Broadhurst listed as EVP, Global Corp Affairs (previously EVP, Global Corp Aff.) in SEC filings |
| Feb 14, 2023 | Thibaut Mongon listed as Exec VP, WW Chair, Cons Health (previously Exec VP, WW Chair, Consumer) in SEC filings |
| Feb 14, 2023 | Robert J Decker listed as VP Corporate Controller (previously Controller, CAO) in SEC filings |
| Feb 14, 2023 | Paula A Johnson became a director |
| Feb 14, 2023 | Kathryn E Wengel listed as EVP, Chief TO and Risk Officer (previously EVP, Chief GSC Officer) in SEC filings |
| Jan 18, 2023 | Joaquin Duato listed as CEO and Chairman of the Board (previously CEO) in SEC filings |
| Dec 2, 2022 | Ashley McEvoy listed as EVP, WW Chair, MedTech (previously EVP, WW Chair, Medical Devices) in SEC filings |
| Nov 30, 2022 | The company announced the departure of Alex Gorsky from the board in an SEC filing |
| Nov 30, 2022 | The company announced the departure of Alex Gorsky from the board in an SEC filing |
| Oct 17, 2022 | Elizabeth Forminard became Executive VP, General Counsel |
| Feb 15, 2022 | Darius Adamczyk became a director |
| Jan 19, 2022 | Joaquin Duato listed as CEO (previously Vice Chair, Exec Committee) in SEC filings |
| Jan 19, 2022 | Joaquin Duato first listed as a director in an SEC filing |
| Jan 19, 2022 | Alex Gorsky no longer listed as Chairman, CEO in SEC filings |
| Jan 3, 2022 | William Hait became Title: Chief External Innovation and Medical Safety Officer |
| Jan 3, 2022 | Vanessa Broadhurst became EVP, Global Corp Aff. |
| Jan 3, 2022 | Mathai Mammen became EVP, Pharm, R&D |
| Jan 3, 2022 | James D. Swanson became EVP, Chief Information Officer |
| Feb 10, 2021 | Michael E Sneed listed as EVP, Global Corp Aff & CCO (previously EVP, Global Corp Aff & COO) in SEC filings |
| Dec 3, 2020 | Nadja West became a director |
| Dec 27, 2019 | Robert J Decker became Controller, CAO |
| Dec 5, 2019 | Mark A Weinberger became a director |
| Dec 5, 2019 | Hubert Joly became a director |
| Apr 25, 2019 | Marillyn A Hewson became a director |
| Mar 1, 2019 | Thibaut Mongon became Exec VP, WW Chair, Consumer |
| Feb 12, 2019 | Paulus Stoffels listed as Vice Chair, Exec Committee (previously Exec VP, Chief Scientific Off) in SEC filings |
| Nov 16, 2018 | Alex Gorsky first listed as a director in an SEC filing |
| Nov 9, 2018 | Joaquin Duato listed as Vice Chair, Exec Committee (previously Exec VP, WW Chair, Pharma) in SEC filings |
| Jul 2, 2018 | Michael E Sneed became EVP, Global Corp Aff & COO |
| Jul 2, 2018 | Kathryn E Wengel became EVP, Chief GSC Officer |
| Jul 2, 2018 | Joseph J Wolk became Exec VP, CFO |
| Jul 2, 2018 | Jennifer L Taubert became EVP, WW Chair, Pharmaceuticals |
| Jul 2, 2018 | Ashley McEvoy became EVP, WW Chair, Medical Devices |
| Apr 26, 2018 | Jennifer A Doudna became a director |
| Feb 14, 2017 | Sandra E Peterson listed as Exec VP, Group WW Chairman (previously Group Worldwide Chairman) in SEC filings |
| Feb 14, 2017 | Peter Fasolo listed as Exec VP, Chief HR Officer (previously VP, Global Human Resources) in SEC filings |
| Feb 14, 2017 | Paulus Stoffels listed as Exec VP, Chief Scientific Off (previously Chief Scientific Officer) in SEC filings |
| Feb 3, 2017 | Michael H Ullmann listed as Exec VP, General Counsel (previously VP, General Counsel) in SEC filings |
Not reported recently (17)
- Anne M Mulcahy · Last reported as a director in an SEC filing dated Apr 29, 2024
- Peter Fasolo · Last reported as Exec VP, Chief HR Officer in an SEC filing dated Feb 20, 2024
- William Hait · Last reported as Title: Chief External Innovation and Medical Safety Officer in an SEC filing dated Feb 20, 2024
- A. Eugene Washington · Last reported as a director in an SEC filing dated Mar 9, 2023
- Thibaut Mongon · Last reported as Exec VP, WW Chair, Cons Health in an SEC filing dated Feb 15, 2023
- Charles Prince · Last reported as a director in an SEC filing dated Feb 17, 2022
- Ronald A Williams · Last reported as a director in an SEC filing dated Feb 17, 2022
- Michael H Ullmann · Last reported as Exec VP, General Counsel in an SEC filing dated Feb 17, 2022
- Mathai Mammen · Last reported as EVP, Pharm, R&D in an SEC filing dated Feb 17, 2022
- Paulus Stoffels · Last reported as Vice Chair, Exec Committee in an SEC filing dated Feb 17, 2021
- Michael E Sneed · Last reported as EVP, Global Corp Aff & CCO in an SEC filing dated Feb 17, 2021
- William D Perez · Last reported as a director in an SEC filing dated Mar 17, 2020
- Ronald A Kapusta · Last reported as Controller, CAO in an SEC filing dated Feb 12, 2019
- Jorge S. Mesquita · Last reported as Exec VP, WW Chair, Consumer in an SEC filing dated Feb 12, 2019
- Dominic J Caruso · Last reported as Exec VP, Finance; CFO in an SEC filing dated Feb 14, 2018
- Sandra E Peterson · Last reported as Exec VP, Group WW Chairman in an SEC filing dated Feb 14, 2018
- Gary J Pruden · Last reported as Exec VP, WW Chair, Med Devices in an SEC filing dated Mar 2, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
JNJ Proposed Insider Sales (Form 144)
Latest: 2026-08-17
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
5 filings
· $58.4M notice value
· 4 unique filers
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Joaquin Duato (2, $44.6M) · Broadhurst Vanessa (1, $5.8M) · Forminard Elizabeth (1, $4.1M) · Taubert Jennifer L (1, $4.0M)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-17 | Taubert Jennifer L | Officer | 15,000 | $3.95M | 2026-08-17 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-08-13 | Duato Joaquin | Officer, Director | 123,291 | $32.20M | 2026-08-13 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-08-06 | Forminard Elizabeth | Officer | 15,918 | $4.09M | 2026-08-06 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-08-05 | Joaquin Duato | CEO, Chariman | 48,480 | $12.36M | 2026-08-05 | J.P. Morgan Securities LLC | — | EDGAR |
| 2026-07-20 | Broadhurst Vanessa | Officer | 23,054 | $5.79M | 2026-07-20 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-06-11 | Wengel Kathryn E | Officer | 10,000 | $2.40M | 2026-06-11 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-02-27 | Decker Robert J | Officer | 4,075 | $1.01M | 2026-02-27 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-02-20 | Schmid Timothy | Officer | 1,322 | $324.8K | 2026-02-20 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-02-18 | Schmid Timothy | Officer | 22,623 | $5.53M | 2026-02-18 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-02-17 | Broadhurst Vanessa | Officer | 6,197 | $1.51M | 2026-02-17 | Fidelity Brokerage Services LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-04-28
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Accession | Link |
|---|---|---|
| 2026-04-28 | 0000200406-26-000089 | EDGAR |
| 2026-04-14 | 0000200406-26-000076 | EDGAR |
| 2026-01-21 | 0000200406-26-000002 | EDGAR |
| 2025-10-14 | 0000200406-25-000201 | EDGAR |
| 2025-09-09 | 0000200406-25-000190 | EDGAR |
| 2025-07-16 | 0000200406-25-000170 | EDGAR |
| 2025-06-10 | 0000200406-25-000152 | EDGAR |
| 2025-04-30 | 0000200406-25-000141 | EDGAR |
| 2025-04-15 | 0000200406-25-000110 | EDGAR |
| 2025-04-03 | 0000200406-25-000106 | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-02-11 | 0000200406-26-000016 | EDGAR |
| 2025-02-13 | 0000200406-25-000038 | EDGAR |
| 2024-02-16 | 0000200406-24-000013 | EDGAR |
| 2023-02-16 | 0000200406-23-000016 | EDGAR |
| 2022-02-17 | 0000200406-22-000022 | EDGAR |
| 2021-02-22 | 0000200406-21-000008 | EDGAR |
| 2020-02-18 | 0000200406-20-000010 | EDGAR |
| 2019-02-20 | 0000200406-19-000009 | EDGAR |
| 2018-02-21 | 0000200406-18-000005 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-04-22 | 0000200406-26-000087 | EDGAR |
| 2025-10-22 | 0000200406-25-000209 | EDGAR |
| 2025-07-24 | 0000200406-25-000178 | EDGAR |
| 2025-04-23 | 0000200406-25-000119 | EDGAR |
| 2024-10-23 | 0000200406-24-000096 | EDGAR |
| 2024-07-25 | 0000200406-24-000075 | EDGAR |
| 2024-05-01 | 0000200406-24-000049 | EDGAR |
| 2023-10-27 | 0000200406-23-000102 | EDGAR |
| 2023-07-31 | 0000200406-23-000082 | EDGAR |
| 2023-04-28 | 0000200406-23-000056 | EDGAR |
ETF Holders
520 ETFs hold JNJ
25 shown · $87.39B total exposure · 1.31% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.87% | $20.3B | — | 2026-09-30 |
| 2 | VOO Vanguard S&P 500 ETF | Vanguard | 0.97% | $16.8B | — | 2026-09-30 |
| 3 | IVV iShares Core S&P 500 ETF | iShares (BlackRock) | 0.97% | $8.6B | $873.6B | 2026-10-22 |
| 4 | SPY State Street® SPDR® S&P 500® ETF Trust | SPDR (State Street) | 0.98% | $7.9B | $810.5B | 2026-10-22 |
| 5 | VTV Vanguard Morningstar Value ETF | Vanguard | 2.42% | $6.1B | — | 2026-09-30 |
| 6 | XLV State Street® Health Care Select Sector SPDR® ETF | SPDR (State Street) | 9.80% | $4.7B | $47.7B | 2026-10-22 |
| 7 | VIG Vanguard Dividend Appreciation ETF | Vanguard | 2.84% | $3.6B | — | 2026-09-30 |
| 8 | VYM Vanguard High Dividend Yield ETF | Vanguard | 2.71% | $2.6B | — | 2026-09-30 |
| 9 | VHT Vanguard Health Care ETF | Vanguard | 8.79% | $1.9B | — | 2026-09-30 |
| 10 | SPYM State Street® SPDR® Portfolio S&P 500® ETF | SPDR (State Street) | 0.98% | $1.8B | $182.5B | 2026-10-22 |
| 11 | IWD iShares Russell 1000 Value ETF | iShares (BlackRock) | 1.70% | $1.4B | $84.5B | 2026-10-22 |
| 12 | DIA State Street® SPDR® Dow Jones Industrial Average® ETF Trust | SPDR (State Street) | 3.01% | $1.4B | $45.7B | 2026-10-22 |
| 13 | DGRO iShares Core Dividend Growth ETF | iShares (BlackRock) | 2.75% | $1.2B | $44.5B | 2026-10-22 |
| 14 | SPMO Invesco S&P 500 Momentum ETF | Invesco | 4.97% | $1.1B | — | 2026-10-22 |
| 15 | QUAL iShares MSCI USA Quality Factor ETF | iShares (BlackRock) | 2.11% | $1.0B | $48.2B | 2026-10-22 |
| 16 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.87% | $837.1M | $95.8B | 2026-10-22 |
| 17 | DYNF iShares U.S. Equity Factor Rotation Active ETF | iShares (BlackRock) | 1.97% | $830.9M | $42.1B | 2026-10-22 |
| 18 | IVW iShares S&P 500 Growth ETF | iShares (BlackRock) | 1.07% | $810.3M | $75.4B | 2026-10-22 |
| 19 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.87% | $766.8M | — | 2026-10-22 |
| 20 | VV Vanguard Morningstar Large-Cap ETF | Vanguard | 0.99% | $751.5M | — | 2026-09-30 |
| 21 | JEPI JPMorgan Equity Premium Income ETF | Nport | 1.66% | $741.2M | — | 2026-06-30 |
| 22 | MTUM iShares MSCI USA Momentum Factor ETF | iShares (BlackRock) | 3.57% | $643.0M | $18.1B | 2026-10-22 |
| 23 | SPYG State Street® SPDR® Portfolio S&P 500® Growth ETF | SPDR (State Street) | 1.07% | $587.9M | $55.0B | 2026-10-22 |
| 24 | SCHX Schwab U.S. Large-Cap ETF | Nport | 0.79% | $576.9M | — | 2026-05-31 |
| 25 | VT Vanguard Total World Stock ETF | Vanguard | 0.54% | $552.9M | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
40.03
TTM Diluted EPS
$6.59
TTM Revenue
$99.33B
TTM Net Income
$16.09B
TTM Op. Cash Flow
$26.16B
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-27 | $25.40B | $210.00M | $0.09 | $7.72B |
| Q2 '26 | 2026-06-28 | $25.31B | $5.53B | $2.27 | $8.62B |
| Q1 '26 | 2026-03-29 | $24.06B | $5.24B | $2.14 | $2.51B |
| Q4 '25 | 2025-12-28 | $24.56B | $5.12B | $2.09 | $7.31B |
| Q3 '25 | 2025-09-28 | $23.99B | $5.15B | $2.12 | $9.17B |
| Q2 '25 | 2025-06-29 | $23.74B | $5.54B | $2.29 | $3.88B |
| Q1 '25 | 2025-03-30 | $21.89B | $11.00B | $4.54 | $4.17B |
| Q4 '24 | 2024-12-29 | $22.52B | $3.43B | $1.41 | $6.98B |
| Q3 '24 | 2024-09-29 | $22.47B | $2.69B | $1.11 | $7.99B |
| Q2 '24 | 2024-06-30 | $22.45B | $4.69B | $1.93 | $5.63B |
| Q1 '24 | 2024-03-31 | $21.38B | $3.25B | $1.34 | $3.66B |
| Q4 '23 | 2023-12-31 | $21.39B | $4.05B | $1.77 | $7.86B |
Q3 2026 • period ending 2026-09-27 • filed 2026-10-21
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
30.60
P/B
7.56
P/S
6.56
EV/EBITDA
19.46
EV/Sales
6.73
ROE
24.8%
ROA
10.5%
Div Yield
1.97%
FCF Yield
4.30%
Debt/Equity
0.44
Current Ratio
—
Market Cap
$642.59B
as of 2026-10-23
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
22.07M
SI % of Float
0.92%
Days to Cover
3.27
Short Vol Ratio
34.0%
Free Float
2.41B
Float %
100.0%
Short interest 2026-09-30 • Short volume 2026-10-23 • Float 2026-07-08